Imides and their derivatives: glutethimide (INN)

In 2024, imides and their derivatives: glutethimide (inn) trade exhibited strong growth, with global flows reaching $1,182,732 and a three-year compound annual growth rate of +90.7% (five-year: +16.5%). The all-time peak of $1,296,629 was recorded in 2001; the current level is 9% below that high-water mark.

Over the 30-year observation window (1995–2024), 62% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is strengthening (+68.7% acceleration).

The supply side is concentrated (Herfindahl-Hirschman Index 0.627). The three largest exporters — China ($1.1M), Sweden ($488.1K), and United States ($431.8K) — collectively dominate supply flows. The leading exporter has grown at +245.6% over the last three years.

On the demand side, importer concentration is concentrated (HHI 0.735). The three largest import markets are Malaysia ($1.0M), Portugal ($229.5K), and China ($224.1K). The largest importing market sources from 2 different supplying countries.

Estimated substitution elasticity: -17.94. Buyers are highly price-sensitive and can switch between suppliers relatively easily.

The dominant trade corridor is China → Malaysia at $826.0K, representing 82.0% of the importer's total demand.

The volatility score for imides and their derivatives: glutethimide (inn) is 50 out of 100, classified as medium. Trade flows are moderately variable, typical for goods with seasonal or cyclical demand patterns.

For market entrants, strong demand tailwinds create a favourable entry environment. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.